Biomarin Pharmaceutical News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.05.18	BioMarin to Attend Upcoming Investor Conference (PR Newswire)
01.05.18	BioMarin Named To Forbes List Of America's Best Mid-size Employers (PR Newswire)
28.04.18	Biotech Stocks Facing FDA Decision In May (RTTNews)
25.04.18	Biomarin Pharmaceutical Inc. Q1 adjusted earnings (RTTNews)
25.04.18	BioMarin Announces First Quarter 2018 Financial Results (PR Newswire)
18.04.18	BioMarin to Host First Quarter 2018 Financial Results Conference Call and Webcast on Wednesday, April 25 at 4:30pm ET (PR Newswire)
09.04.18	Pareteum's Q1 2018 Revenue Expected At $4.1 Million, a 47% Increase over Q1 2017 (PR Newswire)
04.04.18	Nickelodeon Star JoJo Siwa Joins Adventure Game "Star Stable Online" To Inspire And Empower Girls Around The World (PR Newswire)
28.03.18	European Medicines Agency (EMA) Accepts BioMarin's Marketing Application for Pegvaliase MAA for Treatment of Phenylketonuria (PKU) (PR Newswire)
21.03.18	BioMarin's Gene Therapy Manufacturing Facility Recognized with Industry Award (PR Newswire)
06.03.18	BioMarin to Attend Upcoming Investor Conference (PR Newswire)
28.02.18	Rare Disease Day 2018: BioMarin Launches RARE Scholars Scholarship Program (PR Newswire)
22.02.18	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q4 Earnings Report (RTTNews)
22.02.18	BioMarin Announces Fourth Quarter and Full Year 2017 Financial Results (PR Newswire)
07.02.18	BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at WORLDSymposium™ 2018 (PR Newswire)
06.02.18	WORLDSymposium Recognizes BioMarin's Brineura® (cerliponase alfa) with 2018 New Treatment Award (PR Newswire)
05.02.18	BioMarin Announces 20 Presentations at 14th Annual WORLDSymposium™ 2018 (PR Newswire)
24.01.18	BioMarin to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on Thursday, February 22 at 4:30pm ET (PR Newswire)
24.12.17	It's Raining FDA Approvals, SMMT Opens Wallet, AGRX Snubbed Yet Again (RTTNews)
22.12.17	BioMarin Receives Anticipated Notification of PDUFA Extension for Pegvaliase Biologics License Application (BLA) to May 28, 2018 (PR Newswire)
19.12.17	BioMarin Doses First Patient in Global GENEr8-1 Phase 3 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A (PR Newswire)
11.12.17	BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting (PR Newswire)
09.12.17	BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting Concurrent with NEJM... (PR Newswire)
06.12.17	BioMarin Announces Presentations at 59th American Society of Hematology Annual Meeting & Exposition (PR Newswire)
27.11.17	BioMarin Sells Second Priority Review Voucher for $125 Million (PR Newswire)
19.11.17	In The Spotlight: Catalyst Pharmaceuticals (RTTNews)
31.10.17	Ken Riddick Promoted To President And Publisher Of Three McClatchy Media Companies In California (PR Newswire)
31.10.17	BioMarin to Attend Three Upcoming Investor Conferences (PR Newswire)
26.10.17	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q3 Earnings Report (RTTNews)
26.10.17	BioMarin Increases 2017 Non-GAAP Income Guidance - Quick Facts (RTTNews)
26.10.17	BioMarin Announces Third Quarter 2017 Financial Results (PR Newswire)
26.10.17	BioMarin Reports Breakthrough Therapy Designation For Valoctocogene Roxaparvovec (RTTNews)
26.10.17	FDA Grants Breakthrough Therapy Designation for BioMarin's Valoctocogene Roxaparvovec (formerly BMN 270), an Investigational Gene Therapy for Hemophilia A (PR Newswire)
18.10.17	BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York (PR Newswire)
11.10.17	BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York (PR Newswire)
10.10.17	BioMarin to Host Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, October 26 at 4:30 p.m. ET (PR Newswire)
03.10.17	BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors (PR Newswire)
14.09.17	FDA Not Currently Planning to Hold Advisory Committee Meeting for BioMarin's Pegvaliase Biologics License Application (BLA) (PR Newswire)
06.09.17	BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017 (PR Newswire)
05.09.17	BioMarin Announces 3 Platform and 15 Poster Presentations at 13th International Congress of Inborn Errors of Metabolism 2017 (PR Newswire)
30.08.17	APRI Makes 2nd Try, PRQR To Reveal Data On Sep.25, PFE Awaits FDA Decision (RTTNews)
30.08.17	FDA Accepts BioMarin's Pegvaliase BLA And Grants Priority Review Designation (RTTNews)
29.08.17	FDA Accepts BioMarin's Pegvaliase Biologics License Application (BLA) and Grants Priority Review Designation (PR Newswire)
25.08.17	Technical Snapshots for these Biotech Stocks -- Gilead Sciences, Biogen, bluebird bio, and BioMarin Pharma (PR Newswire)
23.08.17	BioMarin Announces Exercise in Full of Underwriters' Option to Purchase Additional 0.599% Senior Subordinated Convertible Notes Due 2024 (PR Newswire)
21.08.17	Forbes Ranks BioMarin 12th Most Innovative Company in the World (PR Newswire)
15.08.17	BioMarin to Attend Upcoming Investor Conferences (PR Newswire)
08.08.17	BioMarin Announces Offering of $450 Million of 0.599% Senior Subordinated Convertible Notes Due 2024 (PR Newswire)
02.08.17	EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q2 Earnings Report (RTTNews)
02.08.17	BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

16.09.24		NASDAQ Composite aktuell: NASDAQ Composite schlussendlich im Minus
16.09.24		NASDAQ-Handel So entwickelt sich der NASDAQ Composite am Nachmittag
16.09.24		Anleger in New York halten sich zurück: NASDAQ Composite am Montagmittag schwächer
16.09.24		Verluste in New York: NASDAQ Composite verliert zum Start
06.08.24		Freundlicher Handel in New York: NASDAQ Composite zum Handelsende im Plus
06.08.24		Freundlicher Handel: NASDAQ Composite am Nachmittag freundlich
06.08.24		Handel in New York: NASDAQ Composite mittags mit grünem Vorzeichen
06.08.24		Börse New York in Grün: NASDAQ Composite zum Start des Dienstagshandels in Grün

16.09.24

NASDAQ Composite aktuell: NASDAQ Composite schlussendlich im Minus

16.09.24

NASDAQ-Handel So entwickelt sich der NASDAQ Composite am Nachmittag

16.09.24

Anleger in New York halten sich zurück: NASDAQ Composite am Montagmittag schwächer

16.09.24

Verluste in New York: NASDAQ Composite verliert zum Start

06.08.24

Freundlicher Handel in New York: NASDAQ Composite zum Handelsende im Plus

06.08.24

Freundlicher Handel: NASDAQ Composite am Nachmittag freundlich

06.08.24

Handel in New York: NASDAQ Composite mittags mit grünem Vorzeichen

06.08.24

Börse New York in Grün: NASDAQ Composite zum Start des Dienstagshandels in Grün

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Biomarin Pharmaceutical Inc.

Aktien Top/Flop

Biomarin Pharmaceutical Peer Group Nachrichten

Meistgelesene Nachrichten